References from scientific journals

Donepezil for dementia due to Alzheimer's disease.

Birks JS, Harvey RJ. Birks JS, et al. Cochrane Database Syst Rev. 2018 Jun 18;6(6):CD001190. doi: 10.1002/14651858.CD001190.pub3. Cochrane Database Syst Rev. 2018. PMID: 29923184 Free PMC article. Review.

OBJECTIVES: To assess the clinical efficacy and safety of donepezil in people with mild, moderate or severe dementia due to Alzheimer's disease; to compare the efficacy and safety of different doses of donepezil; and to assess the effect of donepezil o …
OBJECTIVES: To assess the clinical efficacy and safety of donepezil in people with mild, moderate or severe dementia due to Alzheimer …

Clinical efficacy and safety of donepezil in the treatment of Alzheimer's disease in Chinese patients.

Zhang N, Gordon ML. Zhang N, et al. Clin Interv Aging. 2018 Oct 11;13:1963-1970. doi: 10.2147/CIA.S159920. eCollection 2018. Clin Interv Aging. 2018. PMID: 30349215 Free PMC article. Review.

Donepezil, an acetylcholinesterase inhibitor (AChEI), has been widely used to treat Alzheimer's disease (AD) in China. ...In addition, the therapeutic response to donepezil may be influenced by apolipoprotein E or cytochrome P450 2D6 polymorphism....
Donepezil, an acetylcholinesterase inhibitor (AChEI), has been widely used to treat Alzheimer's disease (AD) in China. ...In a …

Donepezil in the treatment of ischemic stroke: Review and future perspective.

Barfejani AH, Jafarvand M, Seyedsaadat SM, Rasekhi RT. Barfejani AH, et al. Life Sci. 2020 Dec 15;263:118575. doi: 10.1016/j.lfs.2020.118575. Epub 2020 Oct 12. Life Sci. 2020. PMID: 33058916 Review.

As such, adjunct therapies that can protect neurons during acute ischemic phase prior to revascularization have the potential of enhancing functional recovery. Donepezil, an acetylcholinesterase inhibitor, improves cognition and global function in patients with Alzheimer' …
As such, adjunct therapies that can protect neurons during acute ischemic phase prior to revascularization have the potential of enhancing f …

Donepezil ameliorates oxaliplatin-induced peripheral neuropathy via a neuroprotective effect.

Kawashiri T, Shimizu S, Shigematsu N, Kobayashi D, Shimazoe T. Kawashiri T, et al. J Pharmacol Sci. 2019 Jul;140(3):291-294. doi: 10.1016/j.jphs.2019.05.009. Epub 2019 Jul 19. J Pharmacol Sci. 2019. PMID: 31377017 Free article.

Oxaliplatin induces severe peripheral neuropathy. The effect of donepezil, a drug used for treatment of Alzheimer's disease, on oxaliplatin-induced peripheral neuropathy was investigated using both in vivo and in vitro models. ...Therefore, donepezil may be u …
Oxaliplatin induces severe peripheral neuropathy. The effect of donepezil, a drug used for treatment of Alzheimer's disease, o …

Beyond Thiamine: Treatment for Cognitive Impairment in Korsakoff's Syndrome.

Johnson JM, Fox V. Johnson JM, et al. Psychosomatics. 2018 Jul-Aug;59(4):311-317. doi: 10.1016/j.psym.2018.03.011. Epub 2018 Mar 27. Psychosomatics. 2018. PMID: 29751937 Review.

BACKGROUND: Wernicke's encephalopathy is a condition whose treatment many consultation-liaison psychiatrists know quite well. Less clear, however, is the treatment of its dementia disorder descendent, the Korsakoff's syndrome (KS). OBJECTIVE: This article seeks to r …
BACKGROUND: Wernicke's encephalopathy is a condition whose treatment many consultation-liaison psychiatrists know quite well. Less cl …

Induction of lucid dreams: a systematic review of evidence.

Stumbrys T, Erlacher D, Schädlich M, Schredl M. Stumbrys T, et al. Conscious Cogn. 2012 Sep;21(3):1456-75. doi: 10.1016/j.concog.2012.07.003. Epub 2012 Jul 28. Conscious Cogn. 2012. PMID: 22841958 Review.


Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.

Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Hansen RA, et al. Clin Interv Aging. 2008;3(2):211-25. Clin Interv Aging. 2008. PMID: 18686744 Free PMC article. Review.

Pharmacologic treatments for Alzheimer's disease include the cholinesterase inhibitors donepezil, galantamine, and rivastigmine. ...Indirect comparisons also favored donepezil over galantamine with regard to behavior. Across trials, the incidence of adverse e …
Pharmacologic treatments for Alzheimer's disease include the cholinesterase inhibitors donepezil, galantamine, and rivastigmin …

Memantine, Donepezil, or Combination Therapy-What is the best therapy for Alzheimer's Disease? A Network Meta-Analysis.

Guo J, Wang Z, Liu R, Huang Y, Zhang N, Zhang R. Guo J, et al. Brain Behav. 2020 Nov;10(11):e01831. doi: 10.1002/brb3.1831. Epub 2020 Sep 10. Brain Behav. 2020. PMID: 32914577 Free PMC article.

Memantine and donepezil are frequently used in its treatment, both as monotherapy and in combination. ...METHODS: We searched PubMed, Embase, the Cochrane Library, and Wanfang Med Online and China National Knowledge Infrastructure for English and Chinese publications from …
Memantine and donepezil are frequently used in its treatment, both as monotherapy and in combination. ...METHODS: We searched PubMed, …

A review of clinical treatment considerations of donepezil in severe Alzheimer's disease.

Adlimoghaddam A, Neuendorff M, Roy B, Albensi BC. Adlimoghaddam A, et al. CNS Neurosci Ther. 2018 Oct;24(10):876-888. doi: 10.1111/cns.13035. Epub 2018 Jul 29. CNS Neurosci Ther. 2018. PMID: 30058285 Free PMC article. Review.

BACKGROUND: Alzheimer's disease (AD) is a neurodegenerative disorder that affects over 45 million people worldwide. ...It is prescribed as 5 or 10 mg/d and an FDA-approved 23-mg/d dose. METHOD: This review will discuss risks and benefits of donepezil at these doses …
BACKGROUND: Alzheimer's disease (AD) is a neurodegenerative disorder that affects over 45 million people worldwide. ...It is prescrib …

An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer's disease.

Haake A, Nguyen K, Friedman L, Chakkamparambil B, Grossberg GT. Haake A, et al. Expert Opin Drug Saf. 2020 Feb;19(2):147-157. doi: 10.1080/14740338.2020.1721456. Epub 2020 Jan 28. Expert Opin Drug Saf. 2020. PMID: 31976781 Review.

Introduction: Alzheimer's disease (AD) is the most common cause of major neurocognitive disorders with a prevalence in the US of about 5.7 million in 2018. ...Owing to their being a mainstay in the treatment of AD, the safety and efficacy of prescribing these drugs needs t …
Introduction: Alzheimer's disease (AD) is the most common cause of major neurocognitive disorders with a prevalence in the US of abou …